Cooley Recognized as Law360’s Life Sciences Group of the Year
Cooley partners Sanya Sukduang and Marc Recht were quoted in Law360 about Cooley’s recognition as the 2024 Life Sciences Group of the Year. The award was based on the firm’s significant litigation wins and corporate transactions, including its representation of Liquidia in numerous patent disputes, securing a patent infringement verdict for Sight Sciences and the complete dismissal of a derivative action for FibroGen, and advising Amolyt Pharma on its $1.05 billion sale to AstraZeneca and RayzeBio on its $4.1 billion sale to Bristol Myers Squibb.
Sukduang spoke about leading Liquidia on the launch of its new drug, Yutrepia, while Recht discussed Cooley’s representation of RayzeBio in its initial public offering in 2023 and eventual sale in 2024, as well as the firm’s overall life sciences practice.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.